Donald Trump is returning to the world stage. So is his trollingYear-End Stock Surge? Economic Uncertainty Looms.

Here is what to do to keep families safe from accidental shootingsDivisive Rhetoric On Religion Harms Constitutional Unity: Supreme Court Judge

Marsh & McLennan Cos. stock underperforms Tuesday when compared to competitors

Technology stocks led a broad rally on Wall Street Tuesday during a holiday-shortened trading session ahead of Christmas. The S&P 500 rose 1.1% for its third-straight gain. The Dow Jones Industrial Average added 0.9%, and the tech-heavy Nasdaq composite climbed 1.3%. While Big Tech companies, including Apple, Amazon and chip company Broadcom helped push the market higher, the gains were widespread. All told, the S&P 500 rose 65.97 points to 6,040.04. The Dow added 390.08 points to 43,297.03, and the Nasdaq rose 266.24 points to 20,031.13. Treasury yields held steady in the bond market. The yield on the 10-year Treasury was little changed at 4.59%. European markets closed mostly higher. Markets in Asia mostly gained ground. Tuesday’s U.S. market rally comes as the stock market enters what’s historically been a very cheerful season. The last five trading days of each year, plus the first two in the new year, have brought an average gain of 1.3% since 1950. The so-called “Santa rally” also correlates closely with positive returns in January and the upcoming year. So far this month, the U.S. stock market has lost some of its gains since President-elect Donald Trump’s win on Election Day, which raised hopes for faster economic growth and more lax regulations that would boost corporate profits. Worries have risen that Trump’s preference for tariffs and other policies could lead to higher inflation, a bigger U.S. government debt and difficulties for global trade. Even so, the stock market remains on pace to deliver strong returns for 2024. The benchmark S&P 500 is up 26.6% so far this year and remains within roughly 1% of the all-time high it set earlier this month — its latest of 57 record highs this year. U.S. markets are closed today. Wall Street has several economic reports to look forward to this week, including a weekly update on unemployment benefits on Thursday.While the rest of the Notre Dame community figures out whether it's worth paying four figures for a ticket to the College Football Playoff first-round home game against Indiana, the men's basketball team continues to figure out how to survive without Markus Burton. Notre Dame (5-5) hosts its next-to-last nonconference game Wednesday night against Dartmouth (4-4), which plays its sixth contest of a seven-game road trip. The Fighting Irish took a promising step -- and snapped a five-game losing streak -- on Saturday by edging Syracuse 69-64 in their ACC opener. "We needed to be in a close game and we needed to win a close game so our guys can build some belief back," head coach Micah Shrewsberry said. "We can't take any steps back on Wednesday." Without Burton -- the stat sheet-stuffing sophomore point guard who injured the medial collateral ligament in his knee Nov. 26 against Rutgers -- the Irish are struggling to find someone to run the offense, as evidenced by their seven assists versus 15 turnovers against Syracuse. At the same time, players are filling the scoring void. Braeden Shrewsberry poured in a career-high-tying 25 points versus the Orange while hitting 6 of 11 3-point attempts. Tae Davis averaged 12.4 points and 7.2 shots per game when Burton was healthy, but he has upped his mean production to 16.6 points and 12.2 shots in the past five games. Micah Shrewsberry, though, prefers to measure progress on a possession-by-possession basis. "Just the toughness," he said. "There have been times when we haven't gotten the key stop. We haven't gotten the bucket when we quite need it. It gets deflating sometimes." Dartmouth knows that feeling. On Sunday, the Big Green took a one-point lead with 4:03 left in overtime at UIC -- and then failed to score on their final six possessions to suffer a 69-68 loss. The Big Green, who haven't posted a winning season since 1998-99, believe whole-heartedly in launching 3-pointers as they take 48 percent of their shots from behind the arc. Senior Cade Haskins (13.6 ppg) has hit a team-high 28 of 68 3-pointers this season, though fellow senior Ryan Cornish stacks up as the team's top scorer (14.3 ppg), passer (3.0 assists per game) and defender (2.3 steals per game). In its only previous game against a power-conference opponent, Dartmouth upset Boston College 88-83 on Nov. 29. --Field Level Media

Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia. According to GlobalData, Phase II drugs for Streptococcal Pneumonia have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Gamma-PN overview Gamma-PN vaccine is under development for the prevention of Streptococcal pneumonia. The vaccine candidate is administered intranasal and intramuscular. It is an inactivated, gamma-irradiated and un-encapsulated streptococcus pneumoniae strain Rx1. It is prepared by deletion of the unmarked autolysin gene lytA and with the pneumolysin gene ply replaced with an allele encoding a non-toxic pneumolysoid (PdT) using gamma irradiation to inactivate the bacteria. It was also under development for the treatment pneumonococcal sepsis caused by S. pneumoniae strain. GPN Vaccines overview GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and children from the world’s most deadly pathogens. GPN Vaccines lead product Gamma-PN which induce antibodies to all pneumococcal strains. The company’s pipeline product include GPNV-006 which is a randomised, active-controlled, blinded, dose-ranging study of the safety, tolerability, and immunogenicity of Gamma-PN3. GPN Vaccines is headquartered in Griffith, New South Wales, Australia. For a complete picture of Gamma-PN’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .

Horse racing tips: ‘He shapes like a real stayer’ – Templegate’s huge 16-1 NAP can smash the bookies to bits